Preeclampsia biomarkers and related systems and methods
Disclosed herein are methods, kits, tests, and systems for detecting, predicting, monitoring, or ruling out preeclampsia in pregnant women. Also provided herein are novel diagnostic markers, methods of data analysis, assay formats, and kits employing such markers to improve one or more characteristics of a test for identifying or ruling out preeclampsia based on biomarkers from patient samples.
1. A method for detecting a plurality of proteins in a serum sample from blood of a pregnant human female, the method comprising:
obtaining a serum sample derived from a pregnant human female;
contacting the serum sample from the pregnant human female with at least five different probes, each of which has specific affinity for a different protein, wherein the different proteins comprise PLGF, sFlt1, KIM1, FGF21, and CD274; and
detecting a presence of the different proteins based on binding of the at least five different probes to corresponding proteins;
wherein the different proteins comprise no more than 10 proteins.
2. The method of claim 1 , wherein the at least five different probes further comprise a probe with specific affinity for endoglin.
3. The method of claim 1 , wherein the at least five different probes further comprise a probe with specific affinity for decorin.
4. The method of claim 2 , wherein the at least five different probes further comprise a probe with specific affinity for decorin.
5. The method of claim 1 , wherein one or more of the at least five different probes are antibodies or antibody fragments.
6. The method of claim 1 , wherein all of the at least five different probes are antibodies or antibody fragments.
7. The method of claim 1 , wherein the serum sample was obtained from the pregnant female after the pregnant human female has shown one or more symptoms of preeclampsia, wherein the symptoms of preeclampsia are selected from (1) high blood pressure and (2) proteinuria.
8. The method of claim 1 , wherein the presence of at least one of the different proteins is determined using an enzyme-linked immunosorbent assay (ELISA).
9. The method of claim 1 , wherein the serum sample is initially collected from the pregnant human female while in a perinatologist's office, a labor and delivery room, or triage (ER).
10. The method of claim 1 , wherein the biological sample is initially collected from the pregnant human female after gestational week 20.
11. The method of claim 1 , wherein the at least five different probes contact the biological sample in separate reaction vessels for each protein of the different proteins.
12. The method of claim 1 , wherein the contacting the serum sample with the at least five different probes occurs in a single reaction vessel.
13. The method of claim 1 , wherein the presence of at least one of the different proteins is determined using a luminescent oxygen channeling immunoassay.
14. The method of claim 1 , wherein one or more of the at least five different probes are antibodies or antibody fragments selected from FIG. 18 .
15. The method of claim 1 , wherein all of the at least five different probes are antibodies or antibody fragments selected from FIG. 18 .